Диссертация (1141143), страница 15
Текст из файла (страница 15)
StrokePrevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared WithWarfarin in Patients With Non-Valvular Atrial Fibrillation (SPORTIF III): randomisedcontrolled trial // Lancet.– 2003.– Vol. 362.– p. 1691–1698.42.Ezekowitz M.D., Reilly P.A., Nehmiz G., Simmers T.A., Nagarakanti R.,Parcham-Azad K., Pedersen K.E., Lionetti D.A., Stangier J., Wallentin L. Dabigatranwith or without concomitant aspirin compared with warfarin alone in patients withnonvalvular atrial fibrillation (PETRO Study) // Am J Cardiol.– 2007.– Vol.
100.– p.1419–1426.43.Ezekowitz M.D., Smith E.O., Rankin R., Harrison L.H. Jr., Krous H.F.Left atrial mass: diagnostic value of transesophageal 2-dimensional echocardiographyand indium-111 platelet scintigraphy // Am J Cardiol.– 1983.– Vol. 51.– p. 1563–1564.10144.FalconeR.A.,Moradyechocardiographic evaluation ofF.,ArmstrongW.F.Transesophagealleft atrial appendage function and spontaneouscontrast formation after chemical or electrical cardioversion of atrial fibrillation // TheAmerican journal of cardiology.– 1996.– Vol. 78.– p. 435–439.45.Fatkin D., Kelly R.P., Feneley M.P. Relations between left atrialappendage blood flow velocity, spontaneous echocardiographic contrast andthromboembolic risk in vivo // J Am Coll Cardiol.– 1994.– Vol.
23.– p. 961–696.46.Fatkin D., Kuchar D.L., Thorburn C.W., Feneley M.P. Transesophagealechocardiography before and during direct current cardioversion of atrial fibrillation:evidence for atrial stunning as a mechanism of thromboembolic complications // J AmColl Cardiol.– 1994.– Vol. 23.– p. 307–316.47.Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrialfibrillation: report from the Stockholm Cohort of Atrial Fibrillation // Eur Heart J.–2010.– Vol. 31.– p. 967–975.48.Friberg L., Rosenqvist M., Lip G.Y.
Evaluation of risk stratificationschemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation:the Swedish Atrial Fibrillation Cohort study // Eur Heart J.– 2012.– Vol. 33.– p. 1500–1510.49.Friedman H.S., Win M., Hussain A., Sinha A. Effects of cardiacglycosides on atrial contractile dysfunction after short-term atrial fibrillation // Chest.–2000.– Vol.
118.– p. 1116–1126.50.Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W.,Radford M.J. Validation of clinical classification schemes for predicting stroke: resultsfrom the National Registry of Atrial Fibrillation // JAMA.– 2001.– Vol. 285.– p. 2864–2870.51.Gallagher M.M., Hennessy B.J., Edvardsson N. et al.
Emboliccomplications of direct current cardioversion of atrial arrhythmias: association withlow intensity of anticoagulation at the time of cardioversion // J Am Coll Cardiol.–2002.– Vol. 40(5).– p. 926–933.10252.Gowda R.M., Misra D., Khan I.A., Schweitzer P. Acute pulmonary edemaafter successful electrical cardioversion of atrial fibrillation // Am J Ther.– 2003.– Vol.10.– p. 73–74.53.Granger C.B., Alexander J.H., McMurray J.V., Lopes R.D., Hylek E.M.,Hanna M., Al-Khalidi H.R., Ansell J., Atar D., Avezum A., Bahit M.C., Diaz R.,Easton J.D., Ezekowitz J.A., Flaker G., Garcia D., Geraldes M., Gersh B.J., GolitsynS., Goto S., Hermosillo A.G., Hohnloser S.H., Horowitz J., Mohan P., Jansky P., LewisB.S., Lopez-Sendon J.L., Parkhomenko A., Verheugt F.W.A., Jun Zhu and Wallentin L.for the ARISTOTLE Committees and Investigators.
Apixaban versus Warfarin inPatients with Atrial Fibrillation // N Engl J Med.– 2011.– Vol. 365.– p. 981–992.54.Grimm R.A., Stewart W.J., Arheart K. et al. Left atrial appendage"stunning" after electrical cardioversion of atrial flutter: an attenuated responsecompared with atrial fibrillation as the mechanism for lower susceptibility tothromboembolic events // Journal of the American College of Cardiology.– 1997.– Vol.29.– p. 582–589.55.Grimm R.A., Stewart W.J., Maloney J.D. et al. Impact of electricalcardioversion for atrial fibrillation on left atrial appendage function and spontaneousecho contrast: characterization by simultaneous transesophageal echocardiography // JAmColl Cardiol.– 1993.– Vol.
22.– p. 1359–1366.56.Hansen M.L., Jepsen R.M., Olesen J.B., Ruwald M.H., Karasoy D.,Gislason G.H., Hansen J., Kober L., Husted S., Torp Pedersen C. Thromboembolic riskin 16 274 atrial fibrillation patients undergoing direct current cardioversion with andwithout oral anticoagulant therapy. // Europace.– 2015.– Vol. 17.– p. 18–23.57.Hart R.G., Halperin J.L. Atrial fibrillation and thromboembolism: adecade of progress in stroke prevention // Annals of Internal Medicine.– 1999.– Vol.131.– p. 688–695.58.Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotictherapy to prevent stroke in patients who have nonvalvular atrial fibrillation // AnnIntern Med.– 2007.– Vol.
146.– p. 857–867.10359.Hart R.G., Pearce L.A., McBride R. et al. Factors associated withischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012participants in the SPAF I-III clinical trials // Stroke.– 1999.– Vol. 30.– p. 1223–1229.60.Healey J.S., Connolly S.J., Gold M.R. et al. ASSERT Investigators.Subclinical atrial fibrillation and the risk of stroke // N Engl J Med.– 2012.– Vol. 366.–p.
120-129.61.Hoppensteadt D., Fareed J., Klein A.L. et al. Assessment of CardioversionUsing Transesophageal Echocardiography (ACUTE) II Investigators Comparison ofanticoagulant and anti-inflammatory responses using enoxaparin versus unfractionatedheparin for transesophageal echocardiography-guided cardioversion of atrialfibrillation // Am J Cardiol.– 2008.– Vol. 102(7).– p. 842–846.62.Hughes M., Lip G.Y.
Stroke and thromboembolism in atrial fibrillation: asystematic review of stroke risk factors, risk stratification schema and costeffectiveness data // Thromb Haemost.– 2008.– Vol. 99.– p. 295–304.63.Ikram H., Nixon P.G., Arcan T. Left atrial function after electricalconversion to sinus rhythm // Br Heart J.– 1968.– Vol. 30.– p. 80–83.64.Irani W.N., Grayburn P.A., Afridi I. Prevalence of Thrombus, SpontaneousEcho Contrast, and Atrial Stunning in Patients Undergoing Cardioversion of AtrialFlutter: A Prospective Study Using Transesophageal Echocardiography // Circulation.–1997.– Vol.
95.– p. 962–966.65.Ito T., Suwa M., Otake Y. et al. Assessment of left atrial appendagefunction after cardioversion of atrial fibrillation: Relation to left atrial mechanicalfunction // Am Heart J.– 1998.– Vol. 135.– p. 1020–1026.66.Johansson A.K., Juhlin T., Engdahl J., Lind S., Hagwall K., Rorsman C.,Fodor E., Alenholt A., Paul Nordin A., Rosenqvist M., Frick M. Is one monthtreatment with dabigatran before cardioversion of atrial fibrillation sufficient toprevent thromboembolism? // Europace.– 2015.– Vol. 17(10).– p. 1514–1517.67.Kalejs O., Sakne S., Litunenko O., Strelnieks A., Vikmane M., KovalovaM., Kamzola G., Zabunova M., Kupics K., Lejnieks A., Erglis A.
Safety and efficacy104ofDabigatran versus Warfarin in patients with persistent and long-Acting atrialfibrillation undergoing electrical cardioversion // J Am Coll Cardiol.– 2014.– Vol. 63.–p. 328.68.Kalejs O., Sakne S., Litunenko O., Strelnieks A., Vikmane M., KovalovaM., Kamzola G., Zabunova M., Kupics K., Lejnieks A., Erglis A. Two dosagesDabigatran versus Warfarin in patients with high risk of stroke and embolismundergoing electrical cardioversion with persistent and long-acting atrial fibrillation //J Am Coll Cardiol.– 2015.– Vol.
65.– p. 353.69.Khan I.A. Atrial stunning: determinants and cellular mechanisms // AmHeart J.– 2003.– Vol. 145.– p. 787–794.70.Khan I.A. Transient atrial mechanical dysfunction (stunning) aftercardioversion of atrial fibrillation and flutter // Am Heart J.– 2002.– Vol.
144.– p. 11–22.71.Kirchhof P., Auricchio A., Bax J., Crijns H., Camm J., Diener H.C.,Goette A., Hindricks G., Hohnloser S., Kappenberger L., Kuck K.H., Lip G.Y., OlssonB., Meinertz T., Priori S., Ravens U., Steinbeck G., Svernhage E., Tijssen J., VincentA., Breithardt G.. Outcome parameters for trials in atrial fibrillation: executivesummary. Recommendations from a consensus conference organized by the GermanAtrial Fibrillation Competence NETwork (AFNET) and the European Heart RhythmAssociation (EHRA) // Eur Heart J.– 2007.– Vol. 28.– p.
2803–2817.72.Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for themanagement of atrial fibrillation developed in collaboration with EACTS. // Europeanheart journal.– 2016.– Vol. 37 (38).– p. 2893-2962.73.Klein A. L., Grimm R. A., Murray R. D. et al. Use of transesophagealechocardiography to guide cardioversion in patients with atrial fibrillation // N Engl JMed. – 2001. – Vol.
344. – p. 1411–1420.74.Klein A.L., Jasper S.E., Katz W.E. et al. The use of enoxaparin comparedwith unfractionated heparin for short–term antithrombotic therapy in atrial fibrillationpatientsundergoingtransoesophagealechocardiography–guidedcardioversion:105Assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) IIrandomized multicentre study // European Heart Journal.– 2006.– Vol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
